The Anosh Inc Foundation is a nonprofit organization based in Chicago, focused on enhancing lives through programs in ...

With synthetic steroid use declining and clean performance on the rise, CrazyBulk has emerged as the trusted name in legal ...

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at ...

Net Profit Achieved: Q2 2025 marked Hapbee’s first profitable quarter in company history, with net income of $17,988, compared to a net loss of $178,984 in Q1 2025 and a loss of $1.86 million in Q2 ...

Patients were treated with MIPLYFFA in a 48-month open-label extension (OLE) study following the Phase 2/3, randomized, double-blind, placebo-controlled pivotal trial. The OLE data demonstrate that ...

EURneffy is the trade name for neffy® (epinephrine nasal spray) in the United Kingdom. About neffy® neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in ...

Mirdametinib is marketed under the brand name EZMEKLY ® in the European Union and is conditionally approved by the European Commission (EC) for the treatment of symptomatic, inoperable plexiform ...

On 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the disposal of voting securities or voting ...

The Company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on July 22, 2025 under the Company’s existing trading symbol “GBIO” with the new CUSIP number ...

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit ...

WEST PALM BEACH, FLORIDA, July 18, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “ Company ”), today announced that its Board of Directors has approved pursuing ...

Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials Marseille, France, July 18, 2025, 11:00 am CET – ImCheck Therapeutics ...